St. Vincent’s private hospital has invested significantly in the hospital’s radiation therapy treatment center with the installation of C-RAD Catalyst HD™ and Sentinel 4DCT™ systems. The hospital and its patients are the first in Ireland to benefit from C-RAD’s advanced surface tracking systems. The order has a total value of more than 2.5 MSEK.
The Catalyst HD™ will be delivered with the complete software configuration containing modules for Respiratory Gating, Patient Setup and Positioning, and Motion Monitoring. The systems have full integration with the linear accelerator. Through dedicated interfaces the C-RAD system can control the treatment beam in dependency of respiratory motion. The customer also selected C-RAD’s unique audio-visual couching functionality, which supports an interactive gating mode. Delivery and installation of the order is scheduled for December 2016. The installation is expected to go clinical early in 2017.
St. Vincent’s Private Hospital is a registered charity and a not-for-profit organization. The hospital is a member of St. Vincent’s Healthcare Group, based in Dublin.
In the UK and Ireland C-RAD is represented by the company Vertec Scientific Ltd.
The Catalyst HD™ and Sentinel™ systems enable the high-end treatment techniques within radiation therapy that are increasingly common. With this dual solution C-RAD supports the whole 4D treatment chain from imaging to treatment delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue, or for special treatments in which the tumor position depends on the respiratory cycle.
Brian Keane, CEO at St. Vincent’s Private Hospital says:
“St Vincent’s Private Hospital is at the forefront in delivering comprehensive multidisciplinary oncology services to patients from across Ireland. We are committed to delivering the best quality of care to our patients. This new investment in our Radiotherapy Department will ensure we continue to improve patient care in our hospital”.
“Patients will benefit for the advanced treatment techniques supported by the cutting edge C-RAD systems.” says Tim Thurn, CEO of C-RAD. “We welcome the team at St. Vincent’s Private Hospital to the growing group of C-RAD users. I am very pleased that C-RAD can contribute to improved patient care in Dublin and in the world.”
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 08:30 CET on November 16, 2016.
